Cholesterol-lowering Drugs Market Forecast 2015-2025

Nov 24, 2015, 09:00 ET from Visiongain

LONDON, November 24, 2015 /PRNewswire/ --

Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists

What can be expected from the cholesterol-lowering drugs market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.
 
Our 199-page report provides 153 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2025? Our study forecasts revenues in the following cholesterol-lowering drugs submarkets and products:
• Statins and Fixed-Dose Combinations
- Crestor
- Lipitor
- Livalo
- Lescol/Lescol XL
- Zocor
- Vytorin
- Caduet
- Other Statins and Fixed-Dose Combinations (grouped forecast)
• Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs
- Zetia
- Welchol
- Tricor
- Other cholesterol-lowering drugs (grouped forecast)
• PCSK9 Inhibitors
- Praluent
- Repatha


- RN316
- Other PCSK9 Inhibitors (grouped forecast)
• Novel Cholesterol-Lowering Drugs
- Juxtapid
- Kynamro
- MK-0859
- Other novel cholesterol-lowering drugs (grouped forecast)

See revenue forecasts for the leading international markets
How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including:
• US
Japan
Germany
France
Italy
Spain
• UK
China
Brazil
Russia
India

Leading companies and potential for market growth
Overall revenue for the cholesterol-lowering drugs market will reach $24.63bn in 2019, our work forecasts. We predict strong revenue growth through to 2025. Shifts in diets and lifestyles will contribute to rising levels of high cholesterol, while highly disruptive new treatments will revitalise the market

Our work analyses the key companies in the market. See visiongain's analysis of 9 leading companies, including these:
• AstraZeneca
• Merck
• Pfizer
• Kowa
• Daiichi Sankyo
• Abbvie
• Novartis
• Sanofi
• Amgen

A company profile gives you the following information where available:
• Discussion of a company's activities and outlook
• Analysis of products currently on the market as well as pipeline products
• Company news relevant to the market

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect Cholesterol-Lowering Drugs industry?
Our new report discusses issues and events affecting the cholesterol-lowering drugs market. You will find discussions, including qualitative analyses:
• Highly disruptive treatments entering the market
• Increasing potential in both established and emerging markets

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Cholesterol-Lowering Drugs Market Forecast 2015-2025  report helps you
In summary, our 199-page report gives you the following knowledge:
• Revenue forecasts to 2025 for the Cholesterol-Lowering Drugs market - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2025 for submarkets in each - statins and fixed-dose combinations, absorption inhibitors, ion-exchange resins fibrates, PCSK9 inhibitors and novel drugs
• Revenue forecasts to 2025 for the leading regional markets - US, Japan, EU5 and BRIC
• Assessment of 9 leading companies - analysis of cholesterol-lowering products, revenue, news and upcoming product releases
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the cholesterol-lowering drugs market and leading companies. You will find data, trends and predictions. Please order our report now.

Companies Listed

Abbott Laboratories
AbbVie
Accord Healthcare
Aegerion Pharmaceuticals
Alcon
Algorithm SAL
Allergan
Alynlam Pharmaceuticals
Amgen
Apotex
Astellas Pharma
AstraZeneca
Aurobindo
BASF
Bayer
Biomarin Pharmaceuticals
Blu Caribe
Bristol-Myers Squibb
Ciba-Geigy
Daiichi Sankyo
DalCor Pharmaceuticals
Dezima Pharma
Dr Reddy's Laboratories
EGIS Pharmaceuticals
Eli Lilly
Esperion Therapeutics
Eisai
Fresenius Medical Care
Genzyme Corporation
Glenmark
Hetero Laboratories
Impax Laboratories
Intas Pharmaceuticals
Isis Pharmaceuticals
JW Pharmaceutical
Kaneka
Kowa
Kremers Urban Pharmaceuticals
Lek
Lupin
Merck and Co.
Micro Laboratories
Miltenyi-Biotec
Mylan
Novartis
Par Pharmaceuticals
Pfizer
ProEthic Pharmaceuticals
ProNova BioPharma
Ranbaxy
Reckitt Benckiser
Recordati
Regeneron
Roche
Sandoz
Sanofi
Serometrix
Shionogi
Solvay
Sun Pharma
Teva
Torrent Pharmaceuticals
UCB
Valeant
Warner-Lambert
Wockhardt
Zydus Cadila

Organisations Mentioned in the Report
American College of Cardiology
American Heart Association
Department of Pharmaceuticals (India)
European Society of Cardiology
National Health Service
National Heart, Lung, and Blood Institute
United Nations Department of Economic and Social Affairs
US Dietary Guidelines Advisory Committee
US Food and Drug Administration
World Health Organization

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44-(0)20-7336-6100 or click on https://www.visiongain.com/Report/1527/Cholesterol-Lowering-Drugs-Market-Forecast-2015-2025

SOURCE Visiongain